TNFalpha antagonists and methotrexate in the treatment of TNF-mediated disease
First Claim
Patent Images
1. A method for treating or preventing a tumor necrosis factor-mediated disease in an individual in need thereof comprising co-administering methotrexate and a TNFα
- antagonist to said individual, in therapeutically effective amounts.
4 Assignments
0 Petitions
Accused Products
Abstract
Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed is a composition comprising methotrexate and an anti-tumor necrosis factor antibody. TNF-mediated diseases include rheumatoid arthritis, Crohn'"'"'s disease, and acute and chronic immune diseases associated with transplantation.
35 Citations
2 Claims
-
1. A method for treating or preventing a tumor necrosis factor-mediated disease in an individual in need thereof comprising co-administering methotrexate and a TNFα
- antagonist to said individual, in therapeutically effective amounts.
-
2-38. -38. (canceled)
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeThe Kennedy Trust Rheumatology Research
-
Original AssigneeMathilda and Terence Kennedy Institute of Rheumatology Trust
-
InventorsMaini, Ravinder N., Feldmann, Marc
-
Granted Patent
-
Time in Patent OfficeDays
-
Field of Search
-
US Class Current424/145.1
-
CPC Class CodesA61K 2039/505 comprising antibodiesA61K 2039/545 characterised by the dose, ...A61K 2300/00 Mixtures or combinations of...A61K 31/505 Pyrimidines; Hydrogenated p...A61K 31/519 ortho- or peri-condensed wi...A61K 38/1793 for cytokines; for lymphoki...A61K 39/395 Antibodies agglutinins A61K...A61K 39/39541 against normal tissues, cellsA61K 39/3955 against proteinaceous mater...A61K 45/06 Mixtures of active ingredie...A61P 1/00 Drugs for disorders of the ...A61P 19/02 for joint disorders, e.g. a...A61P 29/00 Non-central analgesic, anti...A61P 37/00 Drugs for immunological or ...A61P 37/06 Immunosuppressants, e.g. dr...C07K 16/241 Tumor Necrosis FactorsC07K 2317/24 containing regions, domains...C07K 2319/00 Fusion polypeptide
